Neuroblastoma: Our Clinical Trials

Through clinical trials, our medical experts evaluate the safety and effectiveness of new therapies and diagnostic tools for neuroblastoma. Clinical trials can also help our doctors compare the effectiveness of different aspects of your child’s care, or determine the causes of neuroblastoma.

If your child is eligible to participate in a clinical trial, he or she may have access to new therapies that are not yet available elsewhere. Our clinical research team is highly experienced in selecting children who are most likely to benefit from a particular investigational therapy. They can guide you through the process of choosing the most appropriate clinical trial for your child’s needs.

Here you can find a list of many of Memorial Sloan Kettering’s current clinical trials for neuroblastoma. To learn more about a study, choose from the list below.

Showing 17 trials
Titlesort icon Investigator
Molecular Characterization of Neuroblastic Tumors and Clinical Outcome
[Protocol 00-109]
Cheung, Nai-Kong, MD, PhD
Evaluating the Causes of Cancer in Young Patients
[Protocol 09-068]
Stadler, Zsofia, MD
A Study Offering Treatment with 3F8 and GM-CSF in Patients with High-Risk Neuroblastoma
Relapsed/Refractory
[Protocol 13-260]
Kushner, Brian, MD
A Study Assessing Lower-Dose Radiation Therapy for High-Risk Neuroblastoma
Newly Diagnosed
[Protocol 14-186]
Wolden, Suzanne, MD
A Pilot Phase II Study of Targeted Radiotherapy with 131I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
[Protocol 04-148]
Modak, Shakeel, MD
A Phase II Study of Intrathecal I131-3F8 in Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
[Protocol 05-122]
Kramer, Kim, MD
A Phase II Study of Cyclophosphamide, Topotecan, and Bevacizumab in Patients with Relapsed or Refractory Ewing's Sarcoma and Neuroblastoma
Newly Diagnosed & Relapsed/Refractory
[Protocol 11-183]
Trippett, Tanya, MD
A Phase II Study of Bevacizumab, Irinotecan, and Temozolomide for Relapsed or Refractory Neuroblastoma
[Protocol 10-015]
Modak, Shakeel, MD
A Phase I Trial of a Trivalent Vaccine with Escalating Doses of the Immunological Adjuvant OPT-821 Plus Oral ß-Glucan for High-Risk Neuroblastoma
[Protocol 05-075]
Kushner, Brian, MD
A Phase I Study of the Hu3F8 Antibody plus GM-CSF in Patients with Relapsed/Refractory Neuroblastoma
Relapsed/Refractory
[Protocol 12-230]
Kushner, Brian, MD
A Phase I Study of LEE011 in Children and Adolescents with Malignant Rhabdoid Tumors and Neuroblastoma
Relapsed/Refractory
[Protocol 13-164]
Modak, Shakeel, MD
A Phase I Study of LDK378 in Children with Cancers Containing an ALK Mutation
Relapsed/Refractory
[Protocol 13-235]
Modak, Shakeel, MD
A Phase I Study of Intrathecal Radioimmunotherapy Using 131I-8H9 for Central Nervous System/Leptomeningeal Cancers
[Protocol 03-133]
Kramer, Kim, MD
A Phase I Study of Humanized 3F8 plus Interleukin-2 in Patients with High-Risk Neuroblastoma and GD2-Positive Tumors
Relapsed/Refractory
[Protocol 12-116]
Roberts, Stephen, MD
A Phase I Study of Humanized 3F8 Monoclonal Antibody in Patients with High-Risk Neuroblastoma and GD2-Positive Tumors
[Protocol 11-009]
Basu, Ellen, MD, PhD
A Phase I Study of Difluoromethylornithine and Celecoxib with Cyclophosphamide and Topotecan in Patients with Recurrent or Persistent Neuroblastoma
Relapsed/Refractory
[Protocol 14-187]
Roberts, Stephen, MD
A Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
[Protocol 09-011]
Modak, Shakeel, MD